Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Stopped The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.

Conditions

• Type2 Diabetes
• Dyslipidemia

Interventions

• DRUG: K-877
• DRUG: Placebo

Sponsor

Kowa Research Institute, Inc.

Collaborators

• [object Object]